Last reviewed · How we verify
SIBP MMR Vaccine
The SIBP MMR vaccine works by stimulating the body's immune system to produce antibodies against measles, mumps, and rubella.
The SIBP MMR vaccine works by stimulating the body's immune system to produce antibodies against measles, mumps, and rubella. Used for Prevention of measles, mumps, and rubella in individuals of all ages.
At a glance
| Generic name | SIBP MMR Vaccine |
|---|---|
| Sponsor | Shanghai Institute Of Biological Products |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains weakened or inactivated forms of the measles, mumps, and rubella viruses, which trigger an immune response without causing the actual diseases. The immune system then remembers how to fight these viruses, providing long-term protection against infection.
Approved indications
- Prevention of measles, mumps, and rubella in individuals of all ages
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SIBP MMR Vaccine CI brief — competitive landscape report
- SIBP MMR Vaccine updates RSS · CI watch RSS
- Shanghai Institute Of Biological Products portfolio CI